NeuralTech
NeuralTech Raises $100M Growth to Transform Biotech
NeuralTech Raises $100M Growth in Latest Funding Round
NeuralTech has successfully closed a $100M Growth funding round, marking a significant milestone in the company's growth trajectory. The round was led by GGV Capital, with participation from Thrive Capital.
Company Overview
Founded in 2023 and headquartered in Philadelphia, PA, NeuralTech has established itself in the Biotech space. Leading AI-powered analytics platform transforming data into actionable business insights
With a current valuation of $10B, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $100M Growth
- Valuation: $10B
- Lead Investor: GGV Capital
Future Outlook
As NeuralTech moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free